Market Research Logo

Global Restless Legs Syndrome Market 2015-2019

Global Restless Legs Syndrome Market 2015-2019

About RLS

RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.

Technavio's analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.

Technavio's report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • UCB
  • XenoPort
Other prominent vendors
  • Alexza Pharmaceuticals
  • Astellas Pharma
  • Axxonis Pharma
  • Bayer Healthcare
  • Impax Pharmaceuticals
  • Luitpold Pharmaceuticals
  • Merz Pharmaceuticals
  • Mundipharma
  • Newron Pharmaceuticals
  • Serina Therapeutics
  • Teva Neuroscience
Market driver
  • High unmet medical needs
  • For a full, detailed list, view our report
Market challenge
  • Unknown disease etiology
  • For a full, detailed list, view our report
Market trend
  • Expected entry of drugs with multiple mechanisms and novel technologies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?




Press Release

Technavio Announces the Publication of its Research Report – Global Restless Legs Syndrome Market 2015-2019

Technavio recognizes the following companies as the key players in the gobal restless legs syndrome market: Boehringer Ingelheim, GlaxoSmithKline, UCB and XenoPort

Other Prominent Vendors in the market are: Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics and Teva Neuroscience

Commenting on the report, an analyst from Technavio’s team said: “The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide's mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina's drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors.”

According to the report, the unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. This creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market.

Further, the report states that the unknown disease etiology is one of the major challenges for vendors in the market.

Companies Mentioned

Boehringer Ingelheim, GlaxoSmithKline, UCB, XenoPort, Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics and Teva NeuroscienceBoehringer Ingelheim, GlaxoSmithKline, UCB, XenoPort, Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics, Teva Neuroscience

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Product Profiles
    • Mirapex/Sifrol/Mirapexin
    • Requip
    • Neupro/Leganto
    • HORIZANT/Regnite
  • Introduction
  • Disease Overview
    • Understanding RLS
      • Types of RLS
        • Table Types of RLS
        • Table Prevalence of Primary and Secondary RLS 2014
        • Table Types of RLS based on Onset of Disease
    • Etiology and Pathogenesis
      • Table Etiology of RLS
      • Genetic Factors
      • Iron Deficiency
      • Other Disease Conditions/Medications
      • Neurological Disturbances
    • Signs and Symptoms
      • Table Symptoms of RLS
    • Diagnosis
      • Differential Diagnosis of RLS
        • Table Differential Diagnosis of RLS
    • Management
      • Table Treatment Options for RLS
      • Pharmacological Therapy
      • Non-pharmacological Therapy
    • Epidemiology
      • Table Prevalence of RLS Based on Gender
    • Economic Burden
  • Pipeline Analysis
    • Table Pipeline Portfolio of Global Restless Legs Syndrome Market
    • Key Information on Pipeline Candidates
      • Injectafer
      • Lisuride
      • Incobotulinumtoxin A
      • IPX-159
      • Safinamide
      • AZ-008
      • SER-214
  • Commercial Opportunities
    • Table Commercial Opportunities for Global Restless Legs Syndrome Market
  • Key Brand Analysis
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Restless Legs Syndrome Market 2014-2019 ($ millions)
    • Five Forces Analysis
  • Market Segmentation by Class of Drugs
    • Table Global Restless Legs Syndrome Market by Class of Drugs
    • Dopaminergic Drugs
    • Opioids
    • Anticonvulsants
    • Sedatives and Hypnotics
    • Others
  • Geographical Segmentation
    • Global Restless Legs Syndrome Market by Geography 2014-2019
      • Table Global Restless Legs Syndrome Market by Geography 2014
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table Vendor Ranking 2014
      • UCB
        • Table Neupro: YoY Growth Rate and Revenue 2010-2014 ($ millions)
        • Table Neupro: Region-wise Revenue Comparison 2012-2014 ($ millions)
      • GlaxoSmithKline
        • Table Requip: YoY Growth Rate and Revenue 2010-2014 ($ millions)
        • Table Region-wise Revenue Comparison of Requip 2012-2014 ($ millions)
      • Boehringer Ingelheim
      • XenoPort
        • Table HORIZANT: US Revenue 2013-2014 ($ millions)
        • Table Regnite: Revenue in Japan 2013-2014 ($ millions)
    • Other and Future Prominent Vendors
  • Key Vendor Analysis
    • Boehringer Ingelheim
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Boehringer Ingelheim: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Geographical Segmentation by Revenue 2013
        • Table Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • GlaxoSmithKline
      • Key facts
      • Business overview
      • Business segmentation by revenue 2014
        • Table GlaxoSmithKline: Business segmentation by revenue 2014
      • Business segmentation by revenue 2013 and 2014
        • Table GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
      • Geographical segmentation by revenue 2014
        • Table GlaxoSmithKline: Geographical segmentation by revenue 2014
      • Business strategy
      • Recent developments
      • SWOT analysis
    • UCB
      • Key Facts
      • Business Overview
      • Product Segmentation by Revenue 2013
        • Table UCB: Product Segmentation by Revenue 2013
      • Product Segmentation by Revenue 2012 and 2013
        • Table UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
      • Geographical Segmentation by Revenue 2013
        • Table UCB: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • XenoPort
      • Key Facts
      • Business Overview
      • Business Strategy
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report